

10/535000

JC20 Rec'd PCT/PTD 16 MAY 2005

**IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE**

Serial No. : (U.S. National Phase Appln.  
based on PCT/JP03/14559)

Applicants : Masakazu HATANO et al.

Filed : Concomitantly Herewith

For : THERAPEUTIC AGENT FOR  
GLAUCOMA COMPRISING Rho  
KINASE INHIBITOR AND  
 $\beta$ -BLOCKER

Docket No. : 05318/HG

Customer No.: 01933

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**MAIL STOP PCT**

S I R :

Submitted herewith is a copy of the English-language  
International Search Report PCT/ISA/210 (5 pages) issued in  
International application No. PCT/03/14559, on which the present  
U.S. national phase application is based.

Copies of the references cited in the International Search  
Report have been supplied by WIPO to the USPTO. Therefore,  
copies of the cited references in the International Search Report  
should be on file in the United States, in accordance with  
current U.S. practice.

Express Mail Mailing Label

No.: EV 626 819 641 US

Date of Deposit: MAY 16, 2005


I hereby certify that this paper is  
being deposited with the United States  
Postal Service "Express Mail Post  
Office to Addressee" service under  
37 CFR 1.10 with sufficient postage  
on the date indicated above and is  
addressed to:

MAIL STOP PCT

Commissioner for Patents,

P.O. Box 1450

Alexandria, VA 22313-1450



Dorothy DeFrancesco

In the event that this Paper is late  
filed, and the necessary petition  
for extension of time is not filed  
concurrently herewith, please consider  
this as a Petition for the requisite  
extension of time, and to the extent  
not tendered by check attached hereto,  
authorization to charge the extension  
fee, or any other fee required in  
connection with this Paper to  
Account No. 06-1378.

JC20 Rec'd PCT/PTO 16 MAY 2005

Attached hereto are Forms PTO/SB/08A and PTO/SB/08B, listing the particulars of the references cited in the International Search Report. As mentioned above, copies of the references should already be in the U.S. file, supplied by WIPO.

It is respectfully requested that the Examiner return initialed copies of the attached Forms PTO/SB/08A and PTO/SB/08B to confirm that the publications supplied by WIPO and listed therein have been considered and made of record.

Respectfully submitted,



---

RICHARD S. BARTH  
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.  
767 THIRD AVENUE - 25TH FLOOR  
NEW YORK, NEW YORK 10017-2023  
Tel. Nos. (212) 319-4900  
(212) 319-4551/Ext. 219  
Fax No. (212) 319-5101  
E-Mail Address: BARTH@FHGC-LAW.COM  
RSB/ddf

Encs.: Forms PTO/SB/08A and PBO/SB/08B

Please type a plus sign ☐ inside this box →

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/535000 (U.S. National Phase Appl. based on PCT/JP05/14559)
				Filed	Concomitantly Herewith
				First Named Inventor	Masakazu HATANO
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	05318/HG

## U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No <sup>1</sup>	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

## FOREIGN PATENT DOCUMENTS

Exam Inits*	Cite No <sup>1</sup>	Offc <sup>3</sup>	Document Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>
/G.H./		EP	1034793	A1	Senju Pharmaceu- ticals Co., Ltd.	09-13-2000		
/G.H./		EP	956865	A1	Yoshitomi Pharmaceutical Industries, Ltd.	11-17-1999		
/G.H./		EP	286903	A1	The Trustees of Colombia	10-19-1988		
/G.H./		WO	97/23222	A1	Alcon Laboratories, Inc.	07-03-1997		
/G.H./		WO	02/38158	A1	Pharmacia AB	05-16-2002		
/G.H./		WO	93/16701	A2	Alcon Laboratories, Inc.	09-02-1993		
/G.H./		WO	03/049745	A1	Pharmacia Corp.	06-19-2003		
Examiner Signature		/Gigi Huang/			Date Considered	11/20/2008		

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Place a check here if English translation is attached.

DATE MAILED: MAY 16, 2005

Please type a plus sign inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	(U.S. PATENT OFFICE LABEL BASED ON PCT/JPO3/14559) <b>10/535000</b>
				Filing Date	CONCOMITANTLY HEREWITH
				First Named Inventor	Masakazu HATANO
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	05318/HG

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/G.H./		UEHARA, M. et al., "Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension," <u>Nature</u> , (1997), <u>389</u> , pp. 990 to 994.	
		<del>Mariko ASAHU et al., "Ryokunaisho to Ryokunaisho Chiryo Yakuzai (Fukuraki Chido Maru 1 Dai 10 Kai)," <u>The Pharmaceuticals Monthly</u>, (1996), <u>38(9)</u>, pp. 2311 to 2331.</del>	
		<del>Kuniteru SHIKATO, "1. Ryokunaisho no Takabetsu Ryoho 1. Gairon (Chiryo-yaku no Sontaku o Dou Kangaerunoka)," <u>Ganka</u>, (2002), <u>44(11)</u>, pp. 1443 to 1448.</del>	
		<del>Tatsuro FUKUCHI, "1. Ryokunaisho no Yakubutsu Ryoho 2. Ryokunaisho Chiryo-yaku G. Koko Shinkei Sogaiyaku β Shadanyaku," <u>Ganka</u>, (2002), <u>44(11)</u>, pp. 1458 to 1463.</del>	
		<del>Ikuo HIGASHI et al., "Gonpatsu Kaihaku Ryokunaisho Gyohi Kogan-tatsusho ni Tsuite Ensan Bunazosin Tengan'eki to Maleic Acid Timolol Tengan'eki tonon Heiyo Koka no Kento," <u>The Journal of the Eye</u>, (2002), <u>19(2)</u>, pp. 261 to 266.</del>	
/G.H./		Yuichiro ONAKA et al., "Betaxolol to unoprostone Heiyo Ryoho no Yukosei to Anzensei," <u>The Journal of the Eye</u> , (2000), <u>17(5)</u> , pp. 687 to 690.	
		<del>Hideki TOKUSHIGE, "Ryokunaisho to Ryokunaisho 1. BIO-Clinica (2002), <u>17(13)</u>, pp. 1191 to 1194.</del>	
/G.H./		HOYNG, P.F.J. et al., "Pharmacological Therapy for Glaucoma," <u>A Review of Drugs</u> , (2000), <u>59(3)</u> , pp. 411 to 434.	
Examiner Signature	/Gigi Huang/		Date Considered
			11/20/2008

\* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Place a check here if English translation is attached.

DATE MAILED: MAY 16, 2005